Advertisement
Organisation › Details
Abzena plc (AIM: ABZA)
Abzena provides proprietary technologies and complementary services to enable the development of better biopharmaceuticals. The Group comprises PolyTherics and Antitope which have established a broad suite of services and technologies that are designed to improve the chances of successful development of antibodies and proteins with enhanced therapeutic benefits. Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture. PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals. The Group has built a global customer base over the past decade which includes the majority of the top 20 biopharmaceutical companies, many large and small biotech companies, and academic groups. Abzena is quoted on the AIM segment of the London Stock Exchange under the symbol ABZA. *
Start | 2014-07-10 renamed | |
Group | Abzena (Group) | |
Today | Abzena Ltd. (since 2018) | |
Predecessor | Abzena Ltd. (OLD) | |
Successor | Abzena Ltd. (since 2018) | |
Industry | biopharmaceutical | |
Industry 2 | drug development | |
Person | Burt, John (Abzena 201405– CEO before Antitope + PolyTherics + Thiakis) | |
Person 2 | Smith, Julian (PolyTherics 201309– CFO before Imperial Innovations + RadioScape) | |
Region | London, Greater London | |
Country | United Kingdom (GB) | |
City | n. a. | |
Address record changed: 2022-02-01 | ||
Basic data | Employees | D: 101 to 500 (2018-03-30) |
Currency | GBP | |
Annual sales | 21,950,000 (revenues, consolidated (2017/18) 2018-03-31) | |
Profit | -14,161,000 (2018-03-31) | |
Cash | 6,785,000 (2013-03-31) | |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Abzena (Group)
- [1] Abzena Ltd.. (6/6/23). "Press Release: Abzena Appoints Thomas Castellano as Chief Financial Officer". San Diego, CA....
- [2] Abzena Ltd.. (3/31/22). "Press Release: Abzena Secures $65 Million in Additional Funding to Accelerate Growth and Expand Capacity". San Diego, CA....
- [3] Abzena Ltd.. (2/1/22). "Press Release: Abzena Appoints Kevin Lundquist as Chief Financial Officer". Cambridge & San Diego, CA....
- [4] Abzena Ltd.. (1/20/22). "Press Release: Abzena Appoints Jim Kennamer as SVP and Site Head of North Carolina". Cambridge & San Diego, CA....
- [5] Abzena Ltd.. (7/28/20). "Press Release: Abzena Receives Growth Capital Investment from Newly Launched Biospring Partners". Cambridge, Bristol, PA & San Diego, CA....
- [6] Abzena plc. (8/16/18). "Press Release: Recommended Cash Offer for Abzena plc [NOT FOR RELEASE WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION]"....
- [7] Abzena plc. (8/16/18). "Press Release: Update on Partial Monetisation of Abzena Inside Portfolio". Cambridge....
- [8] Abzena plc. (7/2/18). "Press Release: Abzena and Telix Sign Strategic Manufacturing and Bioconjugation Agreement". Cambridge & Melbourne....
- [9] Abzena plc. (9/19/17). "Press Release: Abzena Appoints Lotta Ljungqvist as Non-Executive Director". Cambridge....
- [10] Abzena plc. (9/14/17). "Press Release: Trading Update". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top